Chengdu Easton Biopharmaceuticals Co., Ltd.
SSE:688513.SS
40.64 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,349.755 | 1,117.121 | 1,170.513 | 1,022.936 | 921.918 | 947.235 | 768.759 | 476.338 | 338.802 | 240.718 | 208.744 | 162.5 |
| Cost of Revenue
| 338.446 | 223.274 | 196.003 | 143.311 | 104.982 | 92.325 | 87.357 | 71.238 | 70.276 | 107.967 | 104.89 | 93.628 |
| Gross Profit
| 1,011.309 | 893.847 | 974.51 | 879.625 | 816.936 | 854.91 | 681.401 | 405.1 | 268.526 | 132.751 | 103.854 | 68.872 |
| Gross Profit Ratio
| 0.749 | 0.8 | 0.833 | 0.86 | 0.886 | 0.903 | 0.886 | 0.85 | 0.793 | 0.551 | 0.498 | 0.424 |
| Reseach & Development Expenses
| 263.856 | 238.491 | 230.786 | 200.695 | 153.908 | 156.572 | 124.396 | 77.225 | 45.558 | 33.495 | 27.968 | 24.927 |
| General & Administrative Expenses
| 26.792 | 18.774 | 18.976 | 17.049 | 18.564 | 52.464 | 15.322 | 25.548 | 31.785 | 54.124 | 42.216 | 35.41 |
| Selling & Marketing Expenses
| 376.94 | 325.67 | 474.137 | 468.102 | 472.053 | 535.262 | 412.054 | 223.567 | 145.374 | 33.475 | 28.652 | 17.458 |
| SG&A
| 403.732 | 344.187 | 493.113 | 485.151 | 490.617 | 587.726 | 427.376 | 249.115 | 177.159 | 87.434 | 70.18 | 53.716 |
| Other Expenses
| 91.741 | 69.433 | 24.503 | -4.036 | -17.827 | -0.665 | -0.807 | 0.202 | 26.094 | 0 | 0 | 0 |
| Operating Expenses
| 759.329 | 652.11 | 748.402 | 681.81 | 626.697 | 743.632 | 534.053 | 331.114 | 228.775 | 89.181 | 67.446 | 52.396 |
| Operating Income
| 251.98 | 241.737 | 260.628 | 244.153 | 198.795 | 114.733 | 149.136 | 74.268 | 39.417 | 41.526 | 30.707 | 12.811 |
| Operating Income Ratio
| 0.187 | 0.216 | 0.223 | 0.239 | 0.216 | 0.121 | 0.194 | 0.156 | 0.116 | 0.173 | 0.147 | 0.079 |
| Total Other Income Expenses Net
| 0.608 | -0.242 | 1.36 | 111.447 | 80.331 | 1.18 | -0.807 | 0.202 | 26.094 | 2.391 | 3.566 | 2.981 |
| Income Before Tax
| 252.588 | 241.495 | 261.988 | 246.919 | 199.051 | 115.912 | 148.329 | 74.47 | 65.511 | 43.917 | 34.272 | 15.792 |
| Income Before Tax Ratio
| 0.187 | 0.216 | 0.224 | 0.241 | 0.216 | 0.122 | 0.193 | 0.156 | 0.193 | 0.182 | 0.164 | 0.097 |
| Income Tax Expense
| 14.354 | 15.065 | 15.468 | 14.492 | 20.889 | 7.301 | 13.309 | 10.105 | 8.195 | 6.297 | 5.04 | 1.061 |
| Net Income
| 238.234 | 226.574 | 246.521 | 232.428 | 178.162 | 108.612 | 135.02 | 64.366 | 57.317 | 37.619 | 29.233 | 14.731 |
| Net Income Ratio
| 0.177 | 0.203 | 0.211 | 0.227 | 0.193 | 0.115 | 0.176 | 0.135 | 0.169 | 0.156 | 0.14 | 0.091 |
| EPS
| 1.36 | 1.28 | 2.05 | 1.94 | 1.48 | 0.9 | 1.5 | 0.72 | 0.66 | 0.43 | 0.35 | 0.18 |
| EPS Diluted
| 1.36 | 1.28 | 2.05 | 1.94 | 1.48 | 0.9 | 1.5 | 0.72 | 0.66 | 0.43 | 0.35 | 0.18 |
| EBITDA
| 339.107 | 319.893 | 324.007 | 281.287 | 233.898 | 144.035 | 173.897 | 98.438 | 61.618 | 61.333 | 43.309 | 21.295 |
| EBITDA Ratio
| 0.251 | 0.286 | 0.277 | 0.275 | 0.254 | 0.152 | 0.226 | 0.207 | 0.182 | 0.255 | 0.207 | 0.131 |